No added val­ue for a drug's new in­di­ca­tion? Price should ad­just, re­searchers say

As more fol­low-on treat­ments with in­cre­men­tal im­prove­ments win ap­proval in the US and Eu­rope, new re­search pub­lished yes­ter­day notes that few­er than half of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.